Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.

Abstract:

:When allogeneic BMT is used for the treatment of leukemia, depletion of T cells from the donor BM to avoid GVHD may be accompanied by persistence of host cells and post-transplant relapse. In this report, a murine model of MHC-compatible BMT was used to show that delayed infusion of immunocompetent donor cells early after T cell-deficient BMT eliminated residual host cells and provided an antileukemic effect without causing lethal GVHD. AKR (H-2k) recipient mice were pre-conditioned with 9 Gy total body irradiation (LD50) and transplanted with 10(7) BM cells from MHC-matched B10.BR donors. These mice did not develop GVHD and became stable, long-term mixed (donor-host) T cell chimeras. In this model, mixed or incomplete donor T cell chimerism was associated with decreased GVL reactivity. AKR hosts that were transplanted with B10.BR bone marrow admixed with 3 x 10(7) B10.BR spleen cells (as a source of T cells) became complete donor T cell chimeras, but they developed severe and lethal GVHD. However, when the infusion of donor spleen cells was delayed until 21 days after BMT, few mice exhibited any clinical signs of GVHD, and > 95% of the mice became long-term survivors. The infused spleen cells eliminated residual host T cells by 21 days after infusion, and most chimeras were able to resist a supralethal challenge with AKR leukemia/lymphoma cells. Thus, post-transplant adoptive immunotherapy with normal mononuclear cells from the marrow donor may be an effective way to eliminate residual disease or treat leukemia relapse after BMT without causing significant GVHD.

journal_name

Bone Marrow Transplant

authors

Johnson BD,Drobyski WR,Truitt RL

subject

Has Abstract

pub_date

1993-04-01 00:00:00

pages

329-36

issue

4

eissn

0268-3369

issn

1476-5365

journal_volume

11

pub_type

杂志文章
  • Successful program to prevent aspergillus infections in children undergoing marrow transplantation: use of nasal amphotericin.

    abstract::Aspergillus infections in the pediatric bone marrow transplant (BMT) patients are usually fatal. We began the use of a prophylactic nasal spray of amphotericin in 1990. This nasal spray was provided in addition to low-dose intravenous amphotericin. During the time of this study, the number of fatal cases of aspergillu...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1700618

    authors: Trigg ME,Morgan D,Burns TL,Kook H,Rumelhart SL,Holida MD,Giller RH

    更新日期:1997-01-01 00:00:00

  • Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus.

    abstract::Transplantation-associated thrombotic microangiopathy (TA-TMA) is a feared complication of allogeneic hematopoietic SCT (HSCT) owing to its high mortality rate. The use of calcineurin inhibitors or sirolimus (SIR) for GVHD prophylaxis has been suggested as a potential risk factor. However, the impact of tacrolimus (TA...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2014.17

    authors: Labrador J,López-Corral L,López-Godino O,Vázquez L,Cabrero-Calvo M,Pérez-López R,Díez-Campelo M,Sánchez-Guijo F,Pérez-López E,Guerrero C,Alberca I,Del Cañizo MC,Pérez-Simón JA,González-Porras JR,Caballero D

    更新日期:2014-05-01 00:00:00

  • Monitoring four herpesviruses in unrelated cord blood transplantation.

    abstract::Cord blood transplantation, which has lower risk of graft-versus-host disease than bone marrow transplantation, might have higher risk of infections. A system to quantify four herpesviruses, CMV, human herpesvirus 6 (HHV6), EBV, varicella-zoster virus using the real-time PCR assay was established and applied for prosp...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702710

    authors: Tanaka N,Kimura H,Hoshino Y,Kato K,Yoshikawa T,Asano Y,Horibe K,Kojima S,Morishima T

    更新日期:2000-12-01 00:00:00

  • Cytotoxic T-lymphocyte antigen 4 haplotype correlates with relapse and survival after allogeneic hematopoietic SCT.

    abstract::CTLA-4 is a negative regulator of activated T cells and the association of CTLA-4 polymorphisms with autoimmune diseases and transplant outcome has been reported. We evaluated the effect of donor CTLA-4 polymorphisms on outcome after allogeneic hematopoietic SCT (HSCT). We analyzed 147 Japanese HLA-matched sibling rec...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2010.319

    authors: Murase M,Nishida T,Onizuka M,Inamoto Y,Sugimoto K,Imahashi N,Murata M,Miyamura K,Kodera Y,Inoko H,Naoe T

    更新日期:2011-11-01 00:00:00

  • Lack of utility of chimerism studies obtained 2-3 months after myeloablative hematopoietic cell transplantation for ALL.

    abstract::Lineage-specific chimerism studies are commonly obtained at several time points after nonmyeloablative hematopoietic cell transplantation to assess the tempo and degree of engraftment, and to monitor graft rejection. For patients who receive myeloablative transplants, the value of frequent chimerism analyses using sen...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2008.155

    authors: Doney K,Loken M,Bryant E,Smith A,Appelbaum F

    更新日期:2008-08-01 00:00:00

  • Patient education in allogeneic hematopoietic cell transplant: what patients wish they had known about quality of life.

    abstract::Quality of life (QOL) is increasingly recognized as an important clinical outcome of hematopoietic cell transplantation (HCT), but patient education is often overlooked. The aim of the current qualitative study was to examine education regarding post-HCT QOL from the patient's perspective. Allogeneic HCT recipients pa...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2013.158

    authors: Jim HS,Quinn GP,Gwede CK,Cases MG,Barata A,Cessna J,Christie J,Gonzalez L,Koskan A,Pidala J

    更新日期:2014-02-01 00:00:00

  • Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin.

    abstract::Between February 1998 and October 1999, 24 patients with advanced leukemia, lymphoma or solid tumors received G-CSF mobilized peripheral blood stem cells (PBSC) from HLA-matched sibling donors after dose-reduced conditioning therapy. Only patients with reduced performance status or major infectious complications, not ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702500

    authors: Bornhäuser M,Thiede C,Schuler U,Platzbecker U,Freiberg-Richter J,Helwig A,Plettig R,Röllig C,Naumann R,Kroschinsky F,Neubauer A,Ehninger G

    更新日期:2000-07-01 00:00:00

  • Treatment of acute graft-versus-host disease with PUVA (psoralen and ultraviolet irradiation): results of a pilot study.

    abstract::Acute graft-versus-host disease (aGVHD) is a frequent and major complication after allogeneic stem cell transplantation. For many years psoralen and ultraviolet (UV)-A light have been used in the treatment of chronic cutaneous graft-versus-host disease, but few patients have received PUVA therapy for aGVHD. We assesse...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701537

    authors: Wiesmann A,Weller A,Lischka G,Klingebiel T,Kanz L,Einsele H

    更新日期:1999-01-01 00:00:00

  • Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease.

    abstract::BU and CY (BU/CY; 200 mg/kg) before HLA-matched sibling allo-SCT in children with sickle cell disease (SCD) is associated with ~85% EFS but is limited by the acute and late effects of BU/CY myeloablative conditioning. Alternatives include reduced toxicity but more immunosuppressive conditioning. We investigated in a p...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/bmt.2014.84

    authors: Bhatia M,Jin Z,Baker C,Geyer MB,Radhakrishnan K,Morris E,Satwani P,George D,Garvin J,Del Toro G,Zuckerman W,Lee MT,Licursi M,Hawks R,Smilow E,Baxter-Lowe LA,Schwartz J,Cairo MS

    更新日期:2014-07-01 00:00:00

  • Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation.

    abstract::Human cytomegalovirus (CMV) is a major cause of death after transplantation. The frequency of pp65-specific T cells was examined in 38 HLA-A2+ stem cell recipients during the first year after transplantation. Patients were divided into four groups based on donor/recipient serostatus: d+/r+ (n=17), d+/r- (n=7), d-/r+ (...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究

    doi:10.1038/sj.bmt.1705585

    authors: Ganepola S,Gentilini C,Hilbers U,Lange T,Rieger K,Hofmann J,Maier M,Liebert UG,Niederwieser D,Engelmann E,Heilbronn R,Thiel E,Uharek L

    更新日期:2007-03-01 00:00:00

  • Prediction of duration and success rate of unrelated hematopoietic stem cell donor searches based on the patient's HLA-DRB1 allele and DRB1-DQB1 haplotype frequencies.

    abstract::Rapid identification of a matched unrelated donor is essential for patients in need of hematopoietic SCT. We carried out a retrospective evaluation of 549 unrelated donor searches (UDSs), which were completed in 2005 for 23 German transplant centers. On the basis of the patient's HLA-DRB1 allele and DRB1-DQB1 haplotyp...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2009.53

    authors: Hirv K,Bloch K,Fischer M,Einsiedler B,Schrezenmeier H,Mytilineos J

    更新日期:2009-10-01 00:00:00

  • Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs.

    abstract::Recombinant human (rHu) G-CSF has been widely used to treat neutropenia and mobilize PBPCs for their autologous and allogeneic transplantation. It shortens neutropenia and thus reduces the frequency of neutropenic fever. We compared the efficiency of glycosylated rHu and non-glycosylated Hu G-CSF in mobilizing hematop...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2009.150

    authors: Ria R,Gasparre T,Mangialardi G,Bruno A,Iodice G,Vacca A,Dammacco F

    更新日期:2010-02-01 00:00:00

  • Relationship between clinical and BK virological response in patients with late hemorrhagic cystitis treated with cidofovir: a retrospective study from the European Group for Blood and Marrow Transplantation.

    abstract::To investigate the relationship between clinical response and modification of BK viremia, we assessed retrospectively 32 cases of hemorrhagic cystitis (HC) after allogeneic hematopoietic SCT that were treated with i.v. cidofovir (CDV). They were 22 men (69%) and 10 women (31%) with a median age of 24 years, range 3-62...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/bmt.2012.247

    authors: Cesaro S,Pillon M,Tridello G,Aljurf M,Martino R,Schroyens W,Nozzoli C,Barba P,Faraci M,Fagioli F,Cappelli B,Cordonnier C,Al-Mohareb F,Floisand Y,Greil J,Panizzolo IS,Santarone S

    更新日期:2013-06-01 00:00:00

  • Correlation of colony-forming cells, long-term culture initiating cells and CD34+ cells in apheresis products from patients mobilized for peripheral blood progenitors with different regimens.

    abstract::Peripheral blood progenitor cell (PBPC) populations used for transplantation were analyzed for the presence of CD34+ cells, colony-forming cells (initial CFC), and long-term culture initiating cells (LTC-IC) cultured on irradiated stroma for 5 weeks. Thirty-eight leukapheresis products were studied from 11 patients wi...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Bender JG,Lum L,Unverzagt KL,Lee W,Van Epps D,George S,Coon J,Ghalie R,McLeod B,Kaizer H

    更新日期:1994-04-01 00:00:00

  • Bone marrow transplantation in sickle cell disease: the Belgian experience.

    abstract::Twenty eight patients underwent bone marrow transplantation (BMT) for sickle cell anemia in Belgium. The patients were originating from Central Africa, were young and symptomatic. Engraftment occurred in all patients and was sustained in 25. In 3 patients, a bone marrow rejection was observed. One of these patients un...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Vermylen C,Cornu G,Ferster A,Ninane J,Sariban E

    更新日期:1993-01-01 00:00:00

  • Does the emergence and persistence of donor-derived leukaemia-reactive cytotoxic T lymphocytes protect patients given an allogeneic BMT from recurrence? Results of a preliminary study.

    abstract::The frequency of CTL precursors (CTLp) directed towards recipient-derived pre-transplant leukaemic blasts (LB) was measured in the peripheral blood of nine children with acute leukaemia and given BMT from either an HLA-identical sibling or a matched unrelated donor (MUD). Patients were evaluated at various time points...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701419

    authors: Montagna D,Locatelli F,Calcaterra V,Comoli P,Moretta A,Giorgiani G,Zecca M,Bonetti F,Giraldi E,Rondini G,Maccario R

    更新日期:1998-10-01 00:00:00

  • Urinary trypsin inhibitor concentration can predict the immunological insult of chemotherapy and complications after bone marrow transplantation.

    abstract::Urinary trypsin inhibitor has attracted attention as an index of the systemic inflammatory response syndrome. In this study, the urine concentration of trypsin inhibitor was measured to compare the immunological insult of conventional chemotherapy and conditioning chemotherapy for bone marrow transplantation. We also ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702755

    authors: Yamada S,Takatsuka H,Takemoto Y,Wada H,Fujimori Y,Okamoto T,Kanamaru A,Kakishita E

    更新日期:2001-01-01 00:00:00

  • Autologous peripheral blood progenitor cell transplantation for non-Hodgkin's lymphoma with extensive bone marrow necrosis.

    abstract::A patient with malignant lymphoma, large cell type and extensive bone marrow necrosis at presentation is reported. Bone marrow necrosis persisted even after a complete remission was induced with standard chemotherapy. Because of this adverse prognostic factor, circulating stem cells were collected and reinfused follow...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1700786

    authors: Khan AM,Yamase H,Tutschka PJ,Bilgrami S

    更新日期:1997-05-01 00:00:00

  • Management of acute graft-versus-host disease.

    abstract::Current graft-versus-host disease (GVHD) prophylaxis is not uniformly successful. Since the development of GVHD has a profound impact on transplant success, treatment is required. The mainstay of therapy has been glucocorticoids (steroids), along with anti-thymocyte globulin, cyclosporine, monoclonal antibodies, and a...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:

    authors: Deeg HJ,Henslee-Downey PJ

    更新日期:1990-07-01 00:00:00

  • Pharmacokinetics of CsA during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation.

    abstract::We investigated the serial changes in the blood CsA concentration during the switch from continuous intravenous infusion to twice-daily oral administration in allogeneic hematopoietic stem cell transplant recipients (n=12). The microemulsion form of CsA, Neoral, was started at twice the last dose in intravenous infusi...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/bmt.2009.316

    authors: Kimura S,Oshima K,Okuda S,Sato K,Sato M,Terasako K,Nakasone H,Kako S,Yamazaki R,Tanaka Y,Tanihara A,Higuchi T,Nishida J,Kanda Y

    更新日期:2010-06-01 00:00:00

  • Autoimmune hemolytic anemia following T cell-depleted allogeneic bone marrow transplantation.

    abstract::The development of immune-mediated hemolytic anemia is a well-recognized complication after allogeneic bone marrow transplantation (BMT). The majority of reported cases, however, have been alloimmune in origin due to ABO or minor red blood cell antigen incompatibilities between the donor and recipient. In this study, ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Drobyski WR,Potluri J,Sauer D,Gottschall JL

    更新日期:1996-06-01 00:00:00

  • Tacrolimus pharmacokinetics in BMT patients.

    abstract::The pharmacokinetics of tacrolimus following its administration as monotherapy or in combination with corticosteroids or methotrexate to 31 BMT patients are presented. All patients received i.v. tacrolimus initially and were subsequently switched to p.o. dosing. Patients received methotrexate by i.v. bolus on post-tra...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1038/sj.bmt.1701054

    authors: Boswell GW,Bekersky I,Fay J,Wingard J,Antin J,Weisdorf D,Maher R,Fitzsimmons W,Nash R

    更新日期:1998-01-01 00:00:00

  • Effect of IL-7 or IL-4 on reconstitution of donor lymphoid cells in congenic murine bone marrow transplantation.

    abstract::IL-7 and IL-4 are known to influence the growth of cells of the lymphoid lineage. In this study, we investigated the effects of in vivo administration of IL-7 or IL-4 in mice subjected to congenic BM transplant. C57BL/6 Ly5.1+ mice were subjected to TBI, followed by transfer of B and T cell-depleted BM from C57BL/6 Ly...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Mathur A,Vallera DA,Taylor PA,Widmer MB,Yang C,Prabhu A,Blazar BR

    更新日期:1995-07-01 00:00:00

  • Stem cell transplantation for mantle cell lymphoma: should it ever be used outside clinical trials?

    abstract::The outlook for patients with mantle cell lymphoma is poor. The reported median survival in most published series is only 3 to 4 years, and even the most favorable prognostic groups have median survival rates of only 5 years, with no evidence of cure. The use of autologous and allogeneic stem cell transplantation in t...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1703255

    authors: Sweetenham JW

    更新日期:2001-11-01 00:00:00

  • Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.

    abstract::To evaluate the efficacy and toxicity of two different etoposide (VP-16) dosages (30 or 45 mg/kg) in combination with busulfan/cyclophosphamide as conditioning therapy followed by stem cell transplantation in acute myeloid leukemia (AML), 90 patients with AML received either 30 mg/kg (n = 60) or 45 mg/kg (n = 30) etop...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702598

    authors: Kröger N,Zabelina T,Sonnenberg S,Krüger W,Renges H,Stute N,Finkenstein F,Mayer U,Holstein K,Fiedler W,Colberg H,Sonnen R,Kuse R,Braumann D,Metzner B,del Valle F,Erttmann R,Kabisch H,Zander AR

    更新日期:2000-10-01 00:00:00

  • Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.

    abstract::Filgrastim (r-metHuG-CSF)-mobilized peripheral blood progenitor cells (PBPC) and unstimulated bone marrow (BM) were evaluated and compared for reconstitution after high-dose chemotherapy in patients with relapsed Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL) with respect to engraftment, overall and relapse-fr...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1038/sj.bmt.1701941

    authors: Kanteti R,Miller K,McCann J,Roitman D,Morelli J,Hurley C,Berkman E,Schenkein D

    更新日期:1999-09-01 00:00:00

  • Effects of cryopreservation on subsets of fetal liver cells.

    abstract::Human fetal livers from 6 to 13 weeks postconception were analysed before and after cryopreservation. The percentages of cell subsets, detected by MoAbs, did not change significantly after cryopreservation. Compared with BM, fetal liver contained significantly smaller subsets of cells identified by MoAbs, with two exc...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Ek S,Ringdén O,Markling L,Dahlberg N,Pschera H,Seiger A,Sundström E,Westgren M

    更新日期:1993-05-01 00:00:00

  • Transplantation of G-CSF mobilized allogeneic peripheral blood stem cells in rabbits.

    abstract::Mobilized peripheral blood precursor cells (PBPC) are used with increasing frequency to restore autologous hematopoiesis following high-dose radio-chemotherapy. The success of this method has aroused interest in the use of mobilized PBPC for allogeneic transplants. This approach would eliminate the need for marrow asp...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Gratwohl A,Baldomero H,John L,Gimmi C,Pless M,Tichelli A,Nissen C,Filipowicz A,Speck B

    更新日期:1995-07-01 00:00:00

  • 'Fetal' erythropoiesis following bone marrow transplantation as estimated by the number of F cells in the peripheral blood.

    abstract::The aim of this study was to define factor(s) influencing fetal erythropoiesis following bone marrow transplantation. Thirty-one transplanted patients (14 males, 17 females) were studied. The underlying diseases were chronic myelogenous leukaemia (CML, 18 patients), acute myeloblastic leukaemia (AML, 7 patients) and a...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Meletis J,Papavasiliou S,Yataganas X,Vavourakis S,Konstantopoulos K,Poziopoulos C,Samarkos M,Michali E,Dalekou M,Eliopoulos G

    更新日期:1994-11-01 00:00:00

  • Factors affecting the outcome of stem cell transplantation from unrelated donors for childhood acute lymphoblastic leukemia in third remission.

    abstract::Between July 1990 and March 2002, 35 consecutive children with ALL in third complete remission (CR3) underwent stem cell transplantation (SCT) from unrelated donors (UD). All patients received CAMPATH-1M 5-20 mg daily for 5 days. Grafts were T-cell depleted in 30 patients, 29 by CAMPATH antibodies and one by CD34 sele...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704958

    authors: Afify Z,Hunt L,Green A,Guttridge M,Cornish J,Oakhill A

    更新日期:2005-06-01 00:00:00